XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $74.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 188.16% from the company’s previous close.

XOMA has been the topic of several other research reports. SVB Leerink initiated coverage on XOMA in a research note on Monday, April 29th. They set an “outperform” rating and a $40.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of XOMA in a report on Monday, April 29th.

XOMA Stock Performance

XOMA stock opened at $25.68 on Tuesday. The company has a debt-to-equity ratio of 1.39, a current ratio of 9.45 and a quick ratio of 9.45. XOMA has a 12 month low of $13.48 and a 12 month high of $27.36. The company has a fifty day moving average price of $24.77 and a two-hundred day moving average price of $23.57. The company has a market cap of $298.92 million, a PE ratio of -6.55 and a beta of 0.93.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). XOMA had a negative return on equity of 26.00% and a negative net margin of 705.23%. The firm had revenue of $1.49 million during the quarter, compared to analyst estimates of $0.96 million. Research analysts expect that XOMA will post -1.76 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

An institutional investor recently bought a new position in XOMA stock. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA Co. (NASDAQ:XOMA) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,778 shares of the biotechnology company’s stock, valued at approximately $212,000. Price T Rowe Associates Inc. MD owned approximately 0.08% of XOMA at the end of the most recent quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.